Loading
Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer.
Jonathan Ledermann led Study 19, the randomised trial showing maintenance olaparib prolongs progression-free survival in platinum-sensitive relapsed ovarian cancer with the largest effect in BRCA-mutant disease, the proof of concept for every subsequent PARP inhibitor maintenance approval. He has led the ICON trials, chaired the Gynecologic Cancer InterGroup, and led ESMO-ESGO ovarian cancer guidelines.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tags ovarian, parp.
Shares PARP, PARP inhibitors, Ovarian cancer and the tags ovarian, parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tags ovarian, parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD), Ovarian cancer and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).